ABSTRACT
AIMS: Human papilloma virus (HPV) has been identified as an aetiological agent in a subset of patients with vulvar squamous cell carcinoma (VSCC). The prognostic role of HPV status in VSCC patients treated with radiotherapy has not yet been determined. We investigated the associations between HPV, p16 and clinical outcome in these women. MATERIALS AND METHODS: Patients undergoing potentially curative radiation treatment for VSCC at a single institution from 2000 to 2009 were retrospectively identified. Those who received definitive or peri-operative radiotherapy as part of treatment, and who had available pathological specimens, were included for analysis. HPV infection was detected using Roche Linear array hybridisation and p16 by immunohistochemistry. The locoregional relapse (LRR) rate was estimated using a cumulative incidence function to account for competing risks. Disease-free survival (DFS) and overall survival were analysed using the Kaplan-Meier method. The median follow-up was 4.9 years. RESULTS: Forty patients were suitable for analysis, with a median age of 69.5 years. HPV was detected in 14/40 (35%) patients, HPV16 being the most common serotype (79%). Patients with HPV-positive tumours had lower 5 year LRR compared with those with HPV-negative tumours (14.3% versus 79.3%, Gray test P = 0.003). Tumour p16 positivity was also associated with lower 5 year LRR (15.4% versus 81.2%, Gray test P = 0.002). Patients with p16-positive tumours had higher 5 year DFS compared with those with p16-negative tumours (62% versus 7%, Log-rank test P = 0.02). CONCLUSIONS: We have identified a favourable prognostic group in VSCC, with p16-positive patients showing improved outcomes. p16 has the potential to be a predictive marker allowing the identification of women more likely to have a favourable response to radiotherapy.
Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/virology , Cyclin-Dependent Kinase Inhibitor p16/analysis , Vulvar Neoplasms/pathology , Vulvar Neoplasms/virology , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Disease-Free Survival , Female , Human papillomavirus 16 , Humans , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Papillomavirus Infections/complications , Prognosis , Retrospective Studies , Vulvar Neoplasms/radiotherapyABSTRACT
OBJECTIVES: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been approved for osteoporosis treatment in adults. Aim of this study was a 48-week, open-label, pilot study of the safety and efficacy of denosumab in 10 children with OI. METHODS: Ten patients (age range: 5.0-11.0 years; at least two years of prior bisphosphonate treatment) with genetically confirmed OI were studied. Denosumab was administered subcutaneously every 12 weeks with 1 mg/kg body weight. Primary endpoint was change of areal bone mineral density (aBMD) using dual energy x-ray absorptiometry of the lumbar spine after 48 weeks. Safety was assessed by bone metabolism markers and adverse event reporting. RESULTS: Mean relative change of lumbar aBMD was +19 % (95%-CI: 7-31%). Lumbar spine aBMD Z-Scores increased from -2.23±2.03 (mean±SD) to -1.27±2.37 (p=0.0006). Mobility did not change (GMFM-88 +2.72±4.62% (p=0.16); one-minute walking test +11.00±15.82 m (p=0.15). No severe side effects occurred. CONCLUSIONS: On average, there was a significant increase in lumbar spine aBMD percent change after 48 weeks of denosumab. There was no change in mobility parameters and no serious adverse events. Further trials are necessary to assess long-term side effects and efficacy.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Denosumab/therapeutic use , Osteogenesis Imperfecta/drug therapy , Absorptiometry, Photon , Bone Density/drug effects , Child , Child, Preschool , Female , Humans , Lumbar Vertebrae/drug effects , Male , Pilot ProjectsABSTRACT
MicroRNAs (miRNAs) play a crucial role in tumor progression and metastasis. We, and others, recently identified a number of miRNAs that are dysregulated in metastatic renal cell carcinoma compared with primary renal cell carcinoma. Here, we investigated three miRNAs that are significantly downregulated in metastatic tumors: miR-192, miR-194 and miR-215. Gain-of-function analyses showed that restoration of their expression decreases cell migration and invasion in renal cell carcinoma cell line models, whereas knockdown of these miRNAs resulted in enhancing cellular migration and invasion abilities. We identified three targets of these miRNAs with potential role in tumor aggressiveness: murine double minute 2, thymidylate synthase, and Smad Interacting protein 1/zinc finger E-box binding homeobox 2. We observed a convergent effect (the same molecule can be targeted by all three miRNAs) and a divergent effect (the same miRNA can control multiple targets) for these miRNAs. We experimentally validated these miRNA-target interactions using three independent approaches. First, we observed that miRNA overexpression significantly reduces the mRNA and protein levels of their targets. In the second, we observed significant reduction of the luciferase signal of a vector containing the 3'UTR of the target upon miRNA overexpression. Finally, we show the presence of inverse correlation between miRNA changes and the expression levels of their targets in patient specimens. We also examined the prognostic significance of miR-215 in renal cell carcinoma. Lower expression of miR-215 is associated with significantly reduced disease-free survival time. These findings were validated on an independent data set from The Cancer Genome Atlas. These results can pave the way to the clinical use of miRNAs as prognostic markers and therapeutic targets.
Subject(s)
Carcinoma, Renal Cell/genetics , Gene Regulatory Networks , Kidney Neoplasms/genetics , MicroRNAs/genetics , Biomarkers, Tumor/genetics , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation , Disease Progression , Gene Expression , Gene Expression Regulation, Neoplastic , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Neoplasm Invasiveness , Prognosis , Proto-Oncogene Proteins c-mdm2/genetics , Proto-Oncogene Proteins c-mdm2/metabolism , RNA Interference , Repressor Proteins/genetics , Repressor Proteins/metabolism , Zinc Finger E-box Binding Homeobox 2ABSTRACT
OBJECTIVE: HPV infection has been associated with deregulation of the PI3K-Akt-mTOR pathway in invasive cervical carcinomas. This 2-stage phase II study assessed the activity of the mTOR inhibitor, temsirolimus, in patients with measurable metastatic and/or locally advanced, recurrent carcinoma of the cervix. METHODS: Temsirolimus 25mg i.v. was administered weekly in 4 week cycles. One response among the first 18 patients was required to proceed to the second stage of accrual. Correlative molecular studies were performed on archival tumor tissue. RESULTS: Thirty-eight patients were enrolled. Thirty-seven patients were evaluable for toxicity and 33 for response. One patient experienced a partial response (3.0%). Nineteen patients had stable disease (57.6%) [median duration 6.5 months (range 2.4-12.0mo)]. The 6-month progression free survival rate was 28% (95% CI: 14-43%). The median progression free survival was 3.52 months [95% CI (1.81-4.70)]. Adverse effects were mild-moderate in most cases and similar to other temsirolimus studies. No toxicity>grade 3 was observed. Assessment of PTEN and PIK3CA by IHC, copy number analyses and PTEN promoter methylation status did not reveal subsets associated with disease stability. CONCLUSION: Single agent temsirolimus has modest activity in cervical carcinoma with about two-thirds of patients exhibiting stable disease. Molecular markers for treatment benefit remain to be identified.
Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasm Recurrence, Local/drug therapy , Protein Kinase Inhibitors/therapeutic use , Sirolimus/analogs & derivatives , TOR Serine-Threonine Kinases/antagonists & inhibitors , Uterine Cervical Neoplasms/drug therapy , Adult , Aged , Class I Phosphatidylinositol 3-Kinases , Disease-Free Survival , Female , Humans , Immunohistochemistry , Middle Aged , PTEN Phosphohydrolase/analysis , Phosphatidylinositol 3-Kinases/analysis , Sirolimus/adverse effects , Sirolimus/therapeutic use , Uterine Cervical Neoplasms/mortalityABSTRACT
Acute ischaemia of the left ventricular apical region has been produced by occluding for 60 min the upper mid-portion of the left anterior descending (LAD) coronary artery in the exposed heart of anaesthetized dogs. The decrease of the blood supply to this region was associated with characteristic morphologic patterns of the subepicardial temperature distribution which has been visualized with the aid of telethermography using an AGA 750 thermovision equipment. The thermographic cardiac images recorded during the progressive development and the restitution of the ischaemic events were evaluated with a new computer-assisted method developed by the authors and the results were described in composite histograms. The validity of the assumption that subepicardial cooling and warming in a particular region could be ascribed to a decrease and increase, respectively, of local flow, was substantiated by computerized simulation of myocardial heat transfer. In both the intact and the ischaemic (collateral-dependent) portions of the heart the issues of the quantitative evaluation of experimental data were indicative of important dynamic factors that elicit, depending upon some partially known individual characteristics, either compensatory adjustments in the entire myocardium (generalized vasodilation) or a demarcation of the infarct (selective flow decrease). Proofs obtained in additional experiments by administering exogenous catecholamines suggest that ischaemically transformed adrenoceptor mechanisms may play a significant role in the latter process. It was concluded that the quantitative thermographic technique developed by the authors is suitable, due to its considerable temporal and spatial resolution, for concurrent analysis of the time course and the gross morphologic details of cardiac ischaemia in vivo.
Subject(s)
Coronary Circulation , Coronary Disease/diagnosis , Thermography , Animals , Dogs , Female , Male , Time FactorsABSTRACT
Brief episodes of severe ischaemic loads have been reported to attenuate or abolish the vascular autoregulatory capacity, including reactive hyperaemic vasodilation, in the coronary bed. It is suggested that the developed loss of the coronary adaptive reserve and the consecutive ultrastructural alterations can be considered an experimental model for the human effort anginal attacks occurring without significant mechanical constriction of the vessels. The functional morphologic patterns in this state were analysed by the new quantitative technique which is based on the computerized evaluation of cardiac thermograms taken with a thermovision (AGA 750) equipment. In the isolated perfused heart of rabbits, the total adaptive loss developed in the overall flow (cessation of reactive hyperaemia) was found to be associated with slow reacting coronary vessels in the cardiac surface, a delayed shift of the computerized thermographic profiles to warmer ranges during reactive hyperaemia. The pattern strongly suggested a redistribution of flow from the subendocardium. In further observations, simulated emergency coronary bypass operations on dog hearts revealed another distinct thermographic pattern: a reduced vascular adaptive range without considerable delay in reactivity. The studies demonstrated the usefulness of quantitative thermography in visualising and differentiating the various types of coronary dysfunction.